News

The first trial showed that in patients with acute ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis, at one year, the primary endpoint of death or nonfatal myocardial

The single pill would target all three major blood lipids – LDL-C “bad” cholesterol, HDL-C “good” cholesterol, and triglycerides, and combines Abbott’s next-generation fenofibrate ABT-335, which is currently

The combination drug contains Merck-developed extended-release niacin and laropiprant – a novel flushing pathway inhibitor. Cordaptive lowered LDL-cholesterol (LDL-C) levels, increased HDL-cholesterol (HDL-C) levels and reduced triglyceride levels

QLT USA expects the launch of Eligard 45mg six-month formulation in 23 European countries follow the implementation of this positive decision in each of the individual countries. The

The NDA for the intravenous formulation of vernakalant hydrochloride, an investigational new drug for the acute conversion of atrial fibrillation, will be reviewed as part of a two-day

The drug eliminates cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients. The successful completion of the clinical trial allows Kiadis Pharma

Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor (DIPG) and will be used in the trial to treat recurrent diffuse intrinsic pontine glioma.

The multi-national trial will include more than 330 wet age-related macular degeneration (AMD) patients and will assess whether bevasiranib administered every eight or 12 weeks is safe and

Hereditary angieoedema (HAE) is a genetic disorder caused by a shortage of C1 inhibitor activity and results in an overreaction of the immune system. The disease is characterized